 Edward Stenehjem
Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antimicrobial Stewardship | 14 | 2024 | 115 | 5.290 |
Why?
| | Hospitals, Community | 7 | 2023 | 50 | 2.940 |
Why?
| | Anti-Bacterial Agents | 22 | 2024 | 1799 | 2.080 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 6 | 2015 | 234 | 1.440 |
Why?
| | Carrier State | 4 | 2015 | 65 | 1.290 |
Why?
| | Staphylococcal Infections | 5 | 2015 | 401 | 1.250 |
Why?
| | Cross Infection | 6 | 2020 | 238 | 1.130 |
Why?
| | Respiratory Tract Infections | 2 | 2023 | 396 | 1.080 |
Why?
| | Ambulatory Care | 9 | 2023 | 538 | 0.730 |
Why?
| | Sinusitis | 1 | 2023 | 221 | 0.680 |
Why?
| | Hospitalization | 16 | 2024 | 2195 | 0.660 |
Why?
| | Drug Resistance, Microbial | 1 | 2018 | 71 | 0.590 |
Why?
| | Anti-Infective Agents | 2 | 2018 | 254 | 0.560 |
Why?
| | Influenza Vaccines | 4 | 2023 | 539 | 0.550 |
Why?
| | Health Plan Implementation | 1 | 2018 | 137 | 0.540 |
Why?
| | Nasal Cavity | 2 | 2015 | 51 | 0.500 |
Why?
| | Practice Patterns, Physicians' | 6 | 2023 | 1294 | 0.500 |
Why?
| | Drug Utilization | 1 | 2016 | 170 | 0.490 |
Why?
| | Community-Acquired Infections | 3 | 2017 | 171 | 0.480 |
Why?
| | Humans | 63 | 2025 | 136783 | 0.450 |
Why?
| | Veterans | 3 | 2015 | 1457 | 0.420 |
Why?
| | Inappropriate Prescribing | 3 | 2023 | 55 | 0.400 |
Why?
| | Population Surveillance | 2 | 2015 | 470 | 0.400 |
Why?
| | Asymptomatic Infections | 1 | 2012 | 27 | 0.400 |
Why?
| | Influenza, Human | 3 | 2023 | 624 | 0.380 |
Why?
| | Ventriculostomy | 1 | 2012 | 21 | 0.380 |
Why?
| | Drug Resistance, Bacterial | 6 | 2020 | 183 | 0.370 |
Why?
| | Bacteriological Techniques | 1 | 2012 | 71 | 0.370 |
Why?
| | Utah | 4 | 2024 | 69 | 0.370 |
Why?
| | Vaccines, Synthetic | 5 | 2022 | 126 | 0.360 |
Why?
| | Mycoses | 1 | 2012 | 79 | 0.360 |
Why?
| | Adult | 29 | 2024 | 37616 | 0.360 |
Why?
| | Central Nervous System Diseases | 1 | 2012 | 69 | 0.360 |
Why?
| | Bacterial Infections | 2 | 2019 | 251 | 0.350 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2012 | 104 | 0.350 |
Why?
| | Prostheses and Implants | 1 | 2012 | 143 | 0.340 |
Why?
| | Sepsis | 3 | 2024 | 611 | 0.330 |
Why?
| | Emergency Service, Hospital | 11 | 2024 | 2050 | 0.320 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1059 | 0.300 |
Why?
| | Outpatients | 2 | 2023 | 393 | 0.290 |
Why?
| | RNA, Messenger | 7 | 2024 | 2831 | 0.290 |
Why?
| | Idaho | 2 | 2018 | 15 | 0.280 |
Why?
| | Immunization, Secondary | 3 | 2022 | 89 | 0.280 |
Why?
| | United States | 14 | 2023 | 14660 | 0.260 |
Why?
| | Ambulatory Care Facilities | 3 | 2021 | 230 | 0.260 |
Why?
| | Delivery of Health Care | 3 | 2023 | 939 | 0.260 |
Why?
| | Vaccination | 6 | 2024 | 1378 | 0.250 |
Why?
| | Research Design | 2 | 2025 | 1107 | 0.250 |
Why?
| | Candidemia | 1 | 2024 | 10 | 0.230 |
Why?
| | Hospitals | 4 | 2023 | 677 | 0.230 |
Why?
| | Middle Aged | 20 | 2024 | 33200 | 0.230 |
Why?
| | Candida | 1 | 2024 | 36 | 0.230 |
Why?
| | Aged, 80 and over | 9 | 2024 | 7569 | 0.220 |
Why?
| | Pneumonia, Bacterial | 2 | 2016 | 116 | 0.220 |
Why?
| | Laboratories | 2 | 2021 | 113 | 0.220 |
Why?
| | Aged | 16 | 2024 | 23729 | 0.210 |
Why?
| | Telemedicine | 2 | 2024 | 847 | 0.200 |
Why?
| | Hospitals, Veterans | 2 | 2015 | 249 | 0.200 |
Why?
| | Viral Vaccines | 1 | 2023 | 98 | 0.190 |
Why?
| | Male | 21 | 2024 | 67361 | 0.190 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2023 | 152 | 0.190 |
Why?
| | Female | 21 | 2024 | 72840 | 0.180 |
Why?
| | Adolescent | 12 | 2024 | 21463 | 0.180 |
Why?
| | Case-Control Studies | 6 | 2023 | 3537 | 0.170 |
Why?
| | Language | 1 | 2023 | 296 | 0.170 |
Why?
| | Cohort Studies | 3 | 2023 | 5718 | 0.170 |
Why?
| | Immunocompromised Host | 1 | 2021 | 203 | 0.160 |
Why?
| | Checklist | 2 | 2018 | 93 | 0.160 |
Why?
| | Clostridium Infections | 1 | 2020 | 71 | 0.150 |
Why?
| | Cooperative Behavior | 2 | 2020 | 443 | 0.150 |
Why?
| | Risk Factors | 7 | 2024 | 10331 | 0.150 |
Why?
| | Vaccines, Combined | 3 | 2023 | 48 | 0.150 |
Why?
| | Community-Based Participatory Research | 1 | 2020 | 159 | 0.150 |
Why?
| | Hospital Bed Capacity | 1 | 2018 | 25 | 0.150 |
Why?
| | Drug Utilization Review | 1 | 2018 | 56 | 0.150 |
Why?
| | Retrospective Studies | 7 | 2024 | 15564 | 0.140 |
Why?
| | Immunization | 1 | 2020 | 410 | 0.140 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2022 | 389 | 0.140 |
Why?
| | Inservice Training | 1 | 2018 | 113 | 0.140 |
Why?
| | Random Allocation | 1 | 2018 | 353 | 0.140 |
Why?
| | Health Services Research | 1 | 2020 | 400 | 0.140 |
Why?
| | Young Adult | 6 | 2024 | 13126 | 0.130 |
Why?
| | Cluster Analysis | 1 | 2018 | 495 | 0.130 |
Why?
| | Documentation | 1 | 2018 | 189 | 0.130 |
Why?
| | Adaptation, Physiological | 1 | 2020 | 546 | 0.120 |
Why?
| | Mass Screening | 3 | 2013 | 1262 | 0.120 |
Why?
| | Pharmacists | 1 | 2018 | 260 | 0.120 |
Why?
| | Patient Readmission | 2 | 2021 | 695 | 0.120 |
Why?
| | Feasibility Studies | 1 | 2019 | 947 | 0.120 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2015 | 23 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 368 | 0.120 |
Why?
| | Mental Disorders | 1 | 2024 | 1075 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 359 | 0.120 |
Why?
| | Molecular Epidemiology | 1 | 2015 | 67 | 0.110 |
Why?
| | Hospital Mortality | 3 | 2023 | 900 | 0.110 |
Why?
| | Physicians | 1 | 2023 | 897 | 0.110 |
Why?
| | Leadership | 1 | 2018 | 380 | 0.110 |
Why?
| | Program Evaluation | 1 | 2018 | 886 | 0.110 |
Why?
| | Isoniazid | 1 | 2013 | 63 | 0.100 |
Why?
| | Vitamin D Deficiency | 1 | 2015 | 184 | 0.100 |
Why?
| | Prospective Studies | 7 | 2022 | 7583 | 0.100 |
Why?
| | Medical Staff, Hospital | 1 | 2013 | 84 | 0.100 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5417 | 0.100 |
Why?
| | Georgia | 1 | 2012 | 84 | 0.100 |
Why?
| | Bacterial Load | 1 | 2012 | 68 | 0.100 |
Why?
| | Intensive Care Units | 2 | 2021 | 802 | 0.100 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2013 | 141 | 0.100 |
Why?
| | Coinfection | 1 | 2013 | 136 | 0.100 |
Why?
| | Infection Control | 1 | 2013 | 158 | 0.100 |
Why?
| | Primary Prevention | 1 | 2013 | 196 | 0.090 |
Why?
| | Antitubercular Agents | 1 | 2013 | 203 | 0.090 |
Why?
| | Decision Support Systems, Clinical | 1 | 2015 | 218 | 0.090 |
Why?
| | Nursing Staff, Hospital | 1 | 2013 | 153 | 0.090 |
Why?
| | Catheter-Related Infections | 1 | 2012 | 80 | 0.090 |
Why?
| | Prostatic Neoplasms | 2 | 2017 | 1031 | 0.090 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2011 | 45 | 0.090 |
Why?
| | Gram-Negative Bacteria | 1 | 2011 | 75 | 0.090 |
Why?
| | Pneumonia | 1 | 2017 | 638 | 0.090 |
Why?
| | Logistic Models | 3 | 2025 | 2060 | 0.080 |
Why?
| | Tuberculosis | 1 | 2013 | 279 | 0.080 |
Why?
| | Risk | 1 | 2012 | 904 | 0.080 |
Why?
| | Occupational Exposure | 1 | 2013 | 337 | 0.080 |
Why?
| | Virulence Factors | 1 | 2011 | 166 | 0.080 |
Why?
| | Deep Brain Stimulation | 1 | 2012 | 153 | 0.080 |
Why?
| | Recurrence | 1 | 2012 | 1058 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2013 | 1323 | 0.070 |
Why?
| | Longitudinal Studies | 1 | 2015 | 2847 | 0.070 |
Why?
| | Models, Biological | 1 | 2014 | 1769 | 0.070 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1942 | 0.070 |
Why?
| | Incidence | 1 | 2012 | 2788 | 0.060 |
Why?
| | Candida tropicalis | 1 | 2024 | 4 | 0.060 |
Why?
| | Immunity, Herd | 1 | 2024 | 5 | 0.060 |
Why?
| | Child, Preschool | 4 | 2023 | 11069 | 0.050 |
Why?
| | Ethiopia | 2 | 2013 | 41 | 0.050 |
Why?
| | Child | 6 | 2023 | 21968 | 0.050 |
Why?
| | Propensity Score | 1 | 2025 | 288 | 0.050 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2023 | 46 | 0.050 |
Why?
| | Clinical Protocols | 1 | 2024 | 268 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2022 | 2030 | 0.050 |
Why?
| | RNA, Messenger, Stored | 1 | 2022 | 7 | 0.050 |
Why?
| | Time-to-Treatment | 1 | 2024 | 203 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 1 | 2024 | 891 | 0.050 |
Why?
| | Vaccination Coverage | 1 | 2023 | 81 | 0.050 |
Why?
| | Proportional Hazards Models | 1 | 2024 | 1260 | 0.050 |
Why?
| | Contraindications | 1 | 2020 | 90 | 0.040 |
Why?
| | Seasons | 1 | 2023 | 544 | 0.040 |
Why?
| | Computer Simulation | 1 | 2025 | 973 | 0.040 |
Why?
| | Clindamycin | 1 | 2020 | 15 | 0.040 |
Why?
| | Daptomycin | 1 | 2020 | 19 | 0.040 |
Why?
| | Carbapenems | 1 | 2020 | 24 | 0.040 |
Why?
| | Immunization Schedule | 1 | 2021 | 197 | 0.040 |
Why?
| | Fluoroquinolones | 1 | 2020 | 50 | 0.040 |
Why?
| | Doxycycline | 1 | 2020 | 61 | 0.040 |
Why?
| | Cephalosporins | 1 | 2020 | 46 | 0.040 |
Why?
| | Policy | 1 | 2020 | 148 | 0.040 |
Why?
| | Risk Assessment | 2 | 2022 | 3429 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1697 | 0.040 |
Why?
| | HIV Infections | 1 | 2013 | 2812 | 0.040 |
Why?
| | Information Dissemination | 1 | 2020 | 217 | 0.040 |
Why?
| | Betacoronavirus | 1 | 2020 | 267 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2019 | 247 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2022 | 736 | 0.030 |
Why?
| | Health Personnel | 1 | 2023 | 698 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 5749 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2020 | 627 | 0.030 |
Why?
| | Clinical Audit | 1 | 2015 | 13 | 0.030 |
Why?
| | Electronic Mail | 1 | 2015 | 61 | 0.030 |
Why?
| | Administration, Oral | 1 | 2017 | 808 | 0.030 |
Why?
| | Mortality | 1 | 2017 | 357 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1063 | 0.030 |
Why?
| | Hand Sanitizers | 1 | 2013 | 2 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2015 | 311 | 0.030 |
Why?
| | Hand Dermatoses | 1 | 2013 | 7 | 0.030 |
Why?
| | Hand Hygiene | 1 | 2013 | 9 | 0.030 |
Why?
| | Patient Isolation | 1 | 2013 | 18 | 0.030 |
Why?
| | World Health Organization | 1 | 2013 | 122 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1513 | 0.030 |
Why?
| | Masks | 1 | 2013 | 62 | 0.030 |
Why?
| | Time Factors | 2 | 2022 | 6792 | 0.020 |
Why?
| | Reminder Systems | 1 | 2013 | 168 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1619 | 0.020 |
Why?
| | Neisseria meningitidis | 1 | 2011 | 23 | 0.020 |
Why?
| | Databases, Factual | 1 | 2017 | 1347 | 0.020 |
Why?
| | Quality Indicators, Health Care | 1 | 2013 | 308 | 0.020 |
Why?
| | Immune Evasion | 1 | 2011 | 58 | 0.020 |
Why?
| | Bacterial Toxins | 1 | 2011 | 105 | 0.020 |
Why?
| | Bacterial Adhesion | 1 | 2011 | 98 | 0.020 |
Why?
| | Locomotion | 1 | 2011 | 104 | 0.020 |
Why?
| | Virulence | 1 | 2011 | 265 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 6731 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2013 | 543 | 0.020 |
Why?
| | Critical Illness | 1 | 2015 | 807 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2013 | 760 | 0.020 |
Why?
| | Physical Examination | 1 | 1988 | 241 | 0.020 |
Why?
| | Rectum | 1 | 1988 | 185 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2013 | 976 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2013 | 1568 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1157 | 0.020 |
Why?
| | Quality Improvement | 1 | 2013 | 1152 | 0.010 |
Why?
| | Abdominal Injuries | 1 | 1985 | 123 | 0.010 |
Why?
| | Wounds, Nonpenetrating | 1 | 1985 | 275 | 0.010 |
Why?
| | Norway | 1 | 1988 | 44 | 0.000 |
Why?
| | Prognosis | 1 | 1985 | 4018 | 0.000 |
Why?
|
|
Stenehjem's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|